Investors then delved into the data. BioNTech was founded in 2008 but had little to show for its work, some investors concluded. At that time, only 250 patients had been treated with the company’s vaccines. Others doubted that BioNTech was better than Moderna Inc., a rival using similar technology, whose …
Read More »How a coronavirus vaccine maker’s stock went from failure to star
